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Abstract
Chronic idiopathic urticaria is a condition that is often controllable with antihistamine therapy. However, some
patients have disease burden that is difficult to manage, non-responsive to antihistamines and often requires
immunosuppressive medications such as corticosteroids or cyclosporine. We present here a study that
demonstrates the effectiveness of omalizumab in treating this condition and the temporal relationship between
improvement and down regulation of the high affinity IgE receptor (FcεRI). For this, blood samples were obtained
from a symptomatic patient before each treatment and processed for flow cytometric analysis of FcεRI levels on
the surface of blood basophils. Down regulation of FcεRI was observed in association with significant clinical
improvement and discontinuation of immunosuppressive medications.
Background
While approximately 20% of the population will experi-
ence an episode of acute urticaria at some point in their
lifetime, only 0.1% will experience the scourge of chronic
urticaria [1]. This disease is characterized by at least
6 weeks of almost daily episodes of intensely pruritic cuta-
neous wheals that typically last less than 24 hours and are
not associated with residual pigmentation. Half of patients
with chronic urticaria are thought to have this disease as a
result of autoimmune phenomenon, while the remaining
patients are designated as having “idiopathic” disease. It
has been estimated that approximately 35-45% of patients
possess autoimmune IgG antibodies that target the alpha
subunit of FcεR Io r ,t oal e s s e re x t e n t ,t a r g e td i r e c t l yt h e
IgE antibody [2]. A link between thyroid autoimmunity
and chronic urticaria has also been observed in a subset of
patients [3]. Consequently, the evaluation of patients with
chronic urticaria may include investigating for thyroid dys-
function and for the presence of microsomal antibodies
and/or anti-thyroperoxidase antibodies.
Treatment of patients with chronic urticaria, autoim-
mune or idiopathic, involves targeting the H1 receptor
with sufficient doses of antihistamines that will control
the patient’s symptoms. When symptoms can not be
controlled with maximal doses of antihistamines, immu-
nosuppressive medications such as corticosteroids or
cyclosporine are often employed. However, the potential
short and long term side effects from these medications
make their use less than desirable for both the clinician
and patient. Omalizumab is a recombinant monoclonal
antibody that selectively binds to IgE and inhibits its
binding to FcεRI on the surface of mast cells and baso-
phils. The beneficial effects of this therapy in the treat-
ment of moderate to severe persistent asthma have been
well documented [4]. However, the off-label use of oma-
lizumab for treatment of chronic urticaria has shown
promise and represents an immunosuppressive sparing
treatment option for patients with disease burden that is
difficult to manage [5]. Omalizumab has also been
shown in a previous study to significantly reduce symp-
toms in patients with documented chronic autoimmune
urticaria [6]. Thus, omalizumab is increasingly becoming
an accepted new treatment modality for use in patients
with recalcitrant chronic urticaria.
Case Presentation
A5 1y e a r - o l dw o m a nw i t hap ast medical history of
well controlled asthma, allergic rhinitis and atopic der-
matitis was referred to our university clinic complain-
ing of chronic urticaria for the previous three years.
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would last less than a day and were intensely pruritic.
Prior to presentation in our clinic, she was treated by
several physicians with various combinations of high
dose first and second generation antihistamines with-
out success. Montelukast offered no benefit when
added to treatment with antihistamines. However,
relief was obtainable with oral prednisone (20 mg/day)
or cyclosporine (200 mg daily in divided doses).
A biopsy was obtained which confirmed the diagnosis
of true urticaria and ruled out urticarial vasculitis.
During the course of her work up, a number of labora-
tory tests were ordered and were unrevealing as to the
potential etiology of her hives (Table 1). She noted no
association of symptoms with food or medications.
Despite frequent monitoring, she was fearful of the
potential toxic effects from cyclosporine after she
experienced a transient decrease in renal function of
unknown significance. Additionally, she was intolerant
of prednisone when used at times in place of cyclos-
porine due weight gain and psychosis. In an effort to
find a more tolerable and effective alternative, treat-
ment was initiated with omalizumab 300 mg every two
weeks. This dose was chosen based upon the severity
of her symptoms and previous successful outcomes [5].
After the first treatment with omalizumab, the patient
noted significant improvement. Over the course of the
subsequent 2 weeks, she was able to wean cyclosporine
down to 25 mg daily without experiencing an urticarial
flare. This was the lowest tol e r a b l ed o s er e q u i r e dt o
prevent flares until the eighth treatment visit at which
time she was able to completely withdraw from cyclos-
porine use. At the start of omalizumab treatment, she
would experience only a generalized sensation of pruri-
tus without visible lesions. This symptom was con-
trolled initially with the addition of diphenhydramine
25 mg every 8 hours, and later with this medication
used only on an as needed basis. Interestingly, a toler-
ance to the sedative effects of diphenhydramine devel-
oped after a few days of scheduled treatment as has
been suggested by other authors [2]. During the course
of the first 28 weeks of therapy she experienced only
three episodes of hives that were easily managed. After
this initial successful time period, her treatments were
spaced to every three weeks with no further symptoms
or complications. There were no immediate or late
phase hypersensitivity reactions experienced by the
patient during treatment with omalizumab.
Prior to treatment with omalizumab and after consent
was obtained, peripheral blood was obtained from the
patient and from a control subject with no history of
urticaria or allergic disease. After collection, samples
were placed on ice, processed within three hours on the
same day of collection and analyzed using dual staining
flow cytometry to measure baseline expression of FcεRI
on the surface of blood basophils (Figure 1). Addition-
ally, expression of FcεRI was measured prior to each
subsequent treatment over a 52 week period (Figure 2).
For these experiments, FITC anti-FcεRI and PE anti-CD
123 antibodies (eBioscience, San Diego, CA), along with
isotype controls, were added to whole blood. The sam-
ple was then treated with BD FACS Lysing Solution (BD
Biosciences, San Jose, CA) to lyse the red blood cells.
After a series of centrifugation and washing steps with
staining buffer (1:10 dilution of PBS and 10% FBS), the
cells were fixed with 2% paraformaldehyde and analyzed
by flow cytometry.
When compared with the control subject, our patient
displayed a five fold greater expression of FcεRI prior to
treatment with omalizumab. After the first 14 days of
treatment, there was an approximate 80% decrease in the
expression of the high affinity IgE receptor that was main-
tained throughout the duration of treatment. This level of
decrease is similar to previous published reports [7].
While mast cells represent the effector cell implicated in
Table 1 Laboratory values prior to treatment
Test Name Result Reference Range
IgE Level 191 IU/mL 0-180 IU/mL
Anti-FcεRI Ab 0.7% 0-5.0%
Thyroid Stimulating Hormone 1.23 mU/L 0.5-5.5 mU/L
Tryptase 5 ng/ml 2-10 ng/ml
Sedimentation rate 4 mm/hr < 20 mm/hr
Helicobacter Pylori IgG Ab Negative
Ab, Antibody.
Figure 1 Mean expression of FcεRI prior to treatment with
omalizumab. Peripheral blood was collected from the patient and
a normal control subject prior to the patient’s first treatment with
omalizumab. Total FcεRI expression was examined in whole blood
by flow cytometry using dual staining with basophil cell surface
markers anti-CD123 (IL-3r) and anti-FcεRI.
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two surface markers found on the surface of basophils. It
has been previously shown that treatment with omalizu-
mab results in a reduction in free IgE and a decrease in
FcεRI on blood basophils [8]. Previous studies have also
reported that after treatment with omalizumab skin mast
cells demonstrate a phenotypic shift and a reduction of
surface FcεRI, albeit at a slower rate than is seen with
blood basophils [9]. The patient in this study experienced
significant improvement after the first treatment, though it
was 14 weeks until she was able to completely withdraw
from cyclosporine use altogether. This may be due to a
slower response for achieving a decrease in mast cell num-
bers, mast cell function and/or mediator release. Indeed,
regulation of mast cell survival is thought to be mediated
in part by IgE-FcεRI dependent pathways [10]. While
further studies are needed to fully understand the mechan-
ism of efficacy with this new treatment modality, our study
points to the importance of decreased FcεRI expression in
this process.
Conclusion
Treatment with omalizumab and the resultant down
regulation of FcεRI expression is temporally associated
with improvement of chronic idiopathic urticaria.
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Figure 2 Change in FcεRI expression during treatment with
omalizumab. Whole blood was collected from the patient prior to
the first treatment with omalizumab (day 0) and prior to each
subsequent treatment day. Total FcεRI expression was examined in
whole blood by flow cytometry using dual staining with basophil
cell surface markers anti-CD123 (IL-3r) and anti-FcεRI.
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